{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:32:03Z","timestamp":1792809123882,"version":"4.5.0"},"reference-count":5,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rbmojournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reproductive BioMedicine Online"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.rbmo.2021.09.019","type":"journal-article","created":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T12:35:14Z","timestamp":1633350914000},"page":"200-203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Treatment of symptomatic uterine adenomyosis with linzagolix, an oral gonadotrophin-releasing hormone antagonist: a pilot study"],"prefix":"10.1016","volume":"44","author":[{"given":"Jacques","family":"Donnez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Donnez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Brethous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Bestel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Garner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Charpentier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Humberstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Loumaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rbmo.2021.09.019_bib0001","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.fertnstert.2018.01.024","article-title":"Role of transvaginal sonography and magnetic resonance imaging in the diagnosis of uterine adenomyosis","volume":"109","author":"Bazot","year":"2018","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.rbmo.2021.09.019_bib0002","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1055\/s-0040-1719016","article-title":"Current and Future Medical Therapies for adenomyosis","volume":"38","author":"Cope","year":"2020","journal-title":"Semin. Reprod."},{"key":"10.1016\/j.rbmo.2021.09.019_bib0003","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.fertnstert.2020.02.114","article-title":"Treatment of endometriosis-associated pain with linzagolix, an oral GnRH antagonist, a randomized clinical trial","volume":"114","author":"Donnez","year":"2020","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.rbmo.2021.09.019_bib0004","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.fertnstert.2020.04.017","article-title":"Gonadotropin-releasing hormone antagonist (linzagolix): a new therapy for uterine adenomyosis","volume":"114","author":"Donnez","year":"2020","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.rbmo.2021.09.019_bib0005","article-title":"Origin and Pathogenic Mechanisms of Uterine Adenomyosis: What is known so far","author":"Stratopoulou","year":"2020","journal-title":"Reprod. Sci."}],"container-title":["Reproductive BioMedicine Online"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472648321004788?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472648321004788?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:22:57Z","timestamp":1761466977000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1472648321004788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":5,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S1472648321004788"],"URL":"https:\/\/doi.org\/10.1016\/j.rbmo.2021.09.019","relation":{},"ISSN":["1472-6483"],"issn-type":[{"value":"1472-6483","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of symptomatic uterine adenomyosis with linzagolix, an oral gonadotrophin-releasing hormone antagonist: a pilot study","name":"articletitle","label":"Article Title"},{"value":"Reproductive BioMedicine Online","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rbmo.2021.09.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd on behalf of Reproductive Healthcare Ltd.","name":"copyright","label":"Copyright"}]}}